Potential and limitations of a 'test and treat' strategy as HIV prevention in the United States

International Journal of Clinical Practice

Volumn 64, Issue 6, 2010, Pages 678-681

  Holtgrave, D R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANONYMOUS TESTING; AWARENESS; CD4 LYMPHOCYTE COUNT; CONTROL STRATEGY; EARLY INTERVENTION; FEASIBILITY STUDY; HEALTH CARE NEED; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MEDICAL DECISION MAKING; PATIENT COUNSELING; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; RISK REDUCTION; SEXUAL TRANSMISSION; SHORT SURVEY; TREATMENT PLANNING; UNITED STATES; VIRUS LOAD;

EARLY DIAGNOSIS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PATIENT-CENTERED CARE; UNITED STATES;

EID: 77950672626     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02381.x     Document Type: Short Survey

References (31)

1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009 373 : 48 57.
2. De Cock KM, Gilks CF, Lo Y-R, Guerma T. Can antiretroviral therapy eliminate HIV transmission? Lancet 2009 373 : 7 9.
3. Garnett GP, Baggaley RF. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2009 373 : 9 11.
4. Epstein H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1078 1079.
5. Ruark A, Shelton JD, Halperin DT, Wawer MJ, Gray RH. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1078.
6. Jurgens R, Cohen R, Tarantola D, Heywood M, Carr R. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1079.
7. Hsieh Y-H, de Arazoza H. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1079 1080.
8. Wilson DP. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1077 1078.
9. Jaffe H, Smith A, Hope T. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1080.
10. Assefa Y, Lera M. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1080.
11. Cohen MS, Mastro TD, Cates W. Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 2009 373 : 1077.
12. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing and immediate antiretroviral therapy - Authors' reply. Lancet 2009 373 : 1080 1081.
13. Wagner BG, Blower S. Voluntary Universal Testing and Treatment is Unlikely to Lead to HIV Elimination: A Modeling Analysis. Available from Nature Precedings. http://precedings.nature.com/documents/3917/version/1 (accessed March 2010).
14. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009 301 : 2380 2382.
15. Kalichman S, Eaton L. Strategies for preventing HIV transmission. JAMA 2009 302 : 1531 author reply 1531-1532).
16. Holtgrave DR. Strategies for preventing HIV transmission. JAMA 2009 302 : 1530 1531. (author reply 1531-1532).
17. Holtgrave DR. Costs and consequences of the US Centers for Disease Control and Prevention's recommendations for opt-out HIV testing. PLoS Med 2007 4 : e194.
18. Dieffenbach CW, Fauci AS. Strategies for preventing HIV transmission: In reply. JAMA 2009 302 : 1531 1532.
19. Holtgrave DR, Hall IH, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977-2006. J Acquir Immune Defic Syndr 2009 50 (2 236 238.
20. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006 20 (10 1447 1450.
21. Hall HI, Song R, Rhodes P et al. Estimation of HIV incidence in the United States. JAMA 2008 300 : 520 529.
22. Centers for Disease Control and Prevention. HIV prevalence estimates - United States, 2006. MMWR 2008 57 : 1073 1076.
23. Holtgrave DR, Anderson T. Utilizing HIV transmission rates to assist in prioritizing HIV prevention services. Int J STD AIDS 2004 15 : 789 792.
24. Holtgrave DR, Pinkerton SD. Can increasing awareness of HIV seropositivity reduce infections by 50% in the United States? J Acquir Immune Defic Syndr 2007 44 : 360 363.
25. Holtgrave DR. Using transmission rates to understand incidence. 2009 National HIV Prevention Conference, Atlanta, GA. August 23-26, 2008 (presentation B01-4).
26. Dowdle WR. The principles of disease elimination and eradication. MMWR 1999 48 (SU01 23 7.
27. Project Inform. Project Inform and CHAMP Lead Think Tank to Develop an Integrated Approach to HIV Testing, Linkage to Care & Treatment to Further Control US Epidemic. Online document dated December 14, 2009; http://www.projectinform.org/news/2009/121409.shtml (accessed February 2010).
28. Hanssens C. Legal and ethical implications of opt-out HIV testing. Clin Infect Dis 2007 45 (Suppl. 4 S232 9.
29. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV. MMWR 2003 52 (RR12 1 24.
30. Margolis AD, Wolitski RJ, Parsons JT, Gömez CA. Are healthcare providers talking to HIV-seropositive patients about safer sex? AIDS 2001 15 : 2335 2337.
31. Metsch LR, Pereyra M, del Rio C et al. Delivery of HIV prevention counseling by physicians at HIV medical care settings in 4 US cities. Am J Public Health 2004 94 : 1186 1192.